



NIH PUBLIC ACCESS

Author Manuscript

Genet Med. Author manuscript; available in PMC 2012 November 08.

Published in final edited form as:

Genet Med. 2012 February ; 14(2): 215–222. doi:10.1038/gim.2011.10.

IRB PERSPECTIVES ON THE RETURN OF INDIVIDUAL RESULTS FROM GENOMIC RESEARCH

Lynn G. Dressler, DrPH^{1,2,3}, Sondra Smolek, PhD^{3,4}, Roselle Ponsaran, MA^{5,7}, Janell M. Markey, MS^{1,2,3}, Helene Starks, PhD, MPH⁸, Nancy Gerson, BS⁷, Susan Lewis, MSSA^{6,7}, Nancy Press, PhD⁸, Eric Juengst, PhD^{3,4}, and Georgia L. Wiesner, MD^{6,7} for the GRRIP Consortium*

⁽¹⁾Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina at Chapel Hill ⁽²⁾Eshelman School of Pharmacy, University of North Carolina at Chapel Hill ⁽³⁾University of North Carolina at Chapel Hill ⁽⁴⁾School of Medicine, University of North Carolina at Chapel Hill ⁽⁵⁾Department of Bioethics, Case Western Reserve University, Cleveland ⁽⁶⁾Department of Genetics, Case Western Reserve University, Cleveland ⁽⁷⁾Case Western Reserve University, Cleveland ⁽⁸⁾University of Washington, Seattle ⁽⁹⁾Oregon Health Sciences University, Portland

Abstract

Purpose—Return of individual research results from genomic studies is a hotly debated ethical issue in genomic research. However, the perspective of key stakeholders—Institutional Review Board (IRB) reviewers—has been missing from this dialogue. This study explores the positions and experiences of IRB members and staff regarding this issue.

Methods—In depth interviews with 31 IRB professionals at six sites across the United States.

Results—IRB professionals agreed that research results should be returned to research participants when results are medically actionable but only if the participants wanted to know the result. Many respondents expected researchers to address the issue of return of results (ROR) in the IRB application and informed-consent document. Many respondents were not comfortable with their expertise in genomics research, and only a few described actual experiences in addressing ROR. Although participants agreed that guidelines would be helpful, most were reticent to develop them in isolation. Even where IRB guidance exists (e.g., CLIA lab certification required for return), in practice, the guidance has been overruled to allow return (e.g., no CLIA lab performs the assay).

Conclusion—An IRB-researcher partnership is needed to help inform responsible and feasible institutional approaches to returning research results.

Corresponding author: Lynn G. Dressler, University of North Carolina, 120 Mason Farm Rd, CB7361, Chapel Hill NC 27599-7361. P: 919-966-9480; F: 919-966-5863; lynn_dressler@unc.edu.

***GRRIP Consortium:** The Genetic Research Review Issues Project (GRRIP) is a collaborative, multi-site consortium examining genomic researchers' and IRB professionals' views, positions and perspectives on several aspects of the review and conduct of human genomic research. Additional members include: Jo Boughman, American Society of Human Genetics, Bethesda; Wylie Burke, University of Washington, Seattle; Karen Edwards, University of Washington; Seattle; William Freeman, Northwest Indian College, Bellingham; Mary Quinn-Griffin, Case Western Reserve University, Cleveland; Amy Lemke, Northwestern University, Chicago; Patricia Marshall, Case Western Reserve University, Cleveland; Pearle O'Rourke, Partners HealthCare Systems, Boston; Susan Brown Trinidad, University of Washington, Seattle.

\$watermark-text

\$watermark-text

\$watermark-text

Keywords

return of results; disclosure of results; genomic research; genetic research; Institutional Review Boards

INTRODUCTION

One of the most common ethical dilemmas in human genomic research is the challenge of deciding whether to tell participants what researchers discover about individuals' genomes.¹⁻⁵ With the accelerating use of genomic analysis techniques, researchers are increasingly encountering research results that are associated with *potential* as well as *known* health implications. Although this challenge was anticipated in the literature since early in the Human Genome Project,⁶ and a robust effort has been devoted to developing recommendations and models to address this issue,^{1, 4, 5, 7-20} currently no national policy exists to guide researchers, research participants or Institutional Review Board (IRB) professionals. In practice, decisions related to return of results (ROR) are left to local institutions.

The 2007 National Institutes of Health (NIH) GWAS Data-Sharing Policy suggests that "contributing institutions and IRBs may wish to establish policies to determine when it is appropriate to return individual findings from research studies."²¹ IRBs are a logical place for researchers to look for guidance on deciding whether and how to return research results, since they are charged with protecting the rights and interests of research participants in the review and approval of human genomic research protocols. Studies show that researchers identify IRBs as the relevant authority in this regard,²² and that IRB Chairs and human subjects professionals recognize that returning results is an important human subjects research issue,^{18, 23} yet few studies have analyzed how IRB professionals are thinking about this issue and what they are doing to address it.

If, in the absence of federal public policy guidance, IRBs are to develop a shared capacity to help investigators address the challenge of returning results, it will be important to understand their baseline experiences and local practices. The purpose of the current study was to begin that assessment by analyzing IRB perspectives and approaches for returning research results of genomic studies to individual research participants. The study is part of a larger effort to evaluate experiences and views of IRBs and genomic researchers in the review and conduct of genetic and genomic research.^{23, 24}

MATERIALS AND METHODS

Population

We invited IRB members and staff at four major academic centers and two research hospitals across the U.S. to participate in semi-structured interviews. We first contacted the IRB director at each site to identify the most appropriate method for recruiting IRB professionals. At the request of several sites to protect the respondents, neither site name nor position on the IRB (e.g., Chair, co-Chair) is reported in this paper. Individuals who had been active members of an IRB within the last two years and whose job responsibilities included the review of biomedical research protocols were eligible to participate.

Approach and Analysis

Focus groups conducted at two of the six sites informed the development of an interview guide that was used in subsequent one-on-one semi-structured interviews. These one-time interviews were conducted mainly in person (and occasionally by phone) and lasted 45-60

minutes. Due to the time limit, not every interview included all questions in the guide, but all respondents answered the following questions: “Do you think results of genetic or genomic research studies should be provided to individual participants? Why or why not? Under what conditions should research results be returned?” These questions also gave respondents an opportunity to describe their experiences addressing this issue in their IRB. All interviews were audio-recorded and transcribed, and assigned a study identification code. No personal identifiers were collected and no master list was maintained that could link the code to the respondent. Verbal consent was obtained from all but one site that required written consent.

We followed criteria established for qualitative methods to assure the rigor and trustworthiness of data collection, coding and analysis procedures.²⁵⁻²⁷ Briefly, transcripts were first checked for accuracy and the interview text was then analyzed for content related to return of research results. After development of a coding schema by the study team, coding was performed independently by two analysts and compared for agreement. Areas of disagreement were resolved through discussion, and on occasion, by a third coder. The ATLAS.ti software program was used to aid in indexing, searching and retrieving sections of data related to ROR. In-depth analysis of the coded data was conducted by team review through an iterative process of analytic induction to document and interpret themes and patterns using a grounded theory approach.²⁸⁻³⁰ Responses by IRB members and staff were initially reviewed separately and then compared. Since we did not observe differences in perspectives between the two groups, all responses in this paper are reported as one group of IRB professionals.

We also collected demographic information, including sex, age, education, profession, years of experience with the IRB, average number of genetic or genomic research studies reviewed per month, and experience conducting or participating in genetic or genomic research.

This study was reviewed and approved by the IRBs at each of the six sites.

RESULTS

Demographics of Respondents

Thirty-one individuals comprising 24 IRB members and 7 staff participated in the interviews, 18 of whom were female. All but one respondent reported experience reviewing genetic or genomic studies on a monthly basis: 20 reported reviewing an average of 1-3, while ten reviewed more than four per month. Eleven reported a current or past role in genetic or genomic research as co-investigator (n=5), consultant (n=3), or research staff (n=3). IRB members represented a spectrum of professions, including 12 health care providers, eight researchers and one each representing law, ethics and a non-scientist community member (one respondent did not report profession).

General perspectives on and experiences with return of individual results

These IRB professionals understood returning individual results as a perplexing issue, describing it as “an incredibly sticky wicket” and “a big kettle of worms.” They described a range of issues that make this topic complicated to address, including the new, fast paced, and “rapidly evolving nature” of genomic research and, its “broad scope”, “with many contexts.” Respondents also described their uncertainty about the reliability of the research result, especially if the result was preliminary, and the psychological consequences of returning results to individual research participants. The frequent and complex inter-relationships among these issues adds to the difficulty in responding to questions about whether individual results should be returned (see Table 1, [P3]).

For many respondents, the interview itself offered the first opportunity to analyze the issues associated with ROR and prompted interest in addressing this topic in their IRB: “Not sure if the IRB has ever really thought about that [return of individual results]...but I think I’ll have a discussion tomorrow.” Several respondents who did not have experience with returning results anticipated that this issue was going to be more prevalent in the near future as genetics become more routinely integrated into study designs. One respondent remarked, “Well, a great many drug protocols now, or even device protocols, are including genetic sub-studies.” Respondents without special expertise in genetics discussed their difficulty evaluating the implications for research participants, especially in the absence of national guidance (see Table 1, [P4]).

Ten respondents had either thought about this issue before (n=5) or had participated in deciding whether to return a genetic or genomic research result (n=5). In these examples, the IRBs’ moral responsibility in addressing this issue was often highlighted (see Table 1 [P21]). In two examples, respondents described situations they faced regarding the decision of returning research results that were not obtained in a Clinical Laboratory Improvement Act (CLIA) approved laboratory. In both situations the research assay was only available in the researcher’s laboratory, and no CLIA-approved laboratory had the capacity to perform the assay. Although their local IRB guidance indicated that only results obtained in CLIA-approved laboratories could be returned, in both situations, this guidance was over-ruled and the individual result was communicated to the research participant. In one of these examples, the respondent reported that a researcher had identified several genes associated with hyper-coagulability in an individual research participant. The IRB considered the return of this result to have a low risk of potential harm and high anticipated benefit to the individual and recommended returning it:

“Well, you know, if you had this knowledge, at a minimum you’d get up several times in a five-hour flight across the country. And that may be about the extent of what you can do, but it might keep somebody from having a stroke. And so, in that case, the IRB, I think, felt pretty strongly that this was probably information that should be shared.” [P21]

Regardless of level of experience or expertise, all respondents were able to describe multiple concerns they associated with ROR, identifying many of the common issues described in the ROR literature.^{1, 9, 11, 13-18, 31} Many concerns centered around the risks of returning a research result and how the research participant would respond to and/or act on that result. Specific concerns included the emotional and psychosocial consequences (e.g., anxiety, worry, family discord), lifestyle changes and decisions (e.g., reproductive choices, employment) and the potential for economic harm (e.g., as a result of losing insurance).

Positions on return of individual results

A spectrum of positions was articulated including the need to respect the research subject’s right to know/not know research results while weighing the potential negative consequences of returning individual results with anticipated benefit. Similar to the literature,^{1, 32} there was general agreement (29/31) that preliminary, unvalidated results should not be returned, although many respondents did not specify what they meant by *preliminary* or *unvalidated*. Respondents discussed the importance of validating results, both analytically and clinically (Table 1, [P15],[P23]).

Unique positions were also articulated. A respondent indicated that, based on ethical and moral principles, research results should almost always be returned (Table 1, [P16]). Another respondent indicated that because “it is still research”, the mutation status should be returned, but not the interpretation of what that mutation means (e.g., the mutation may be associated with developing a certain disease or responding to a certain drug).

Respondents also discussed the concept of future consideration of research results and the importance of the reliability and utility of the research result, both now and in the future. Nearly one third (n=10) of our respondents highlighted the need to consider how a currently uncertain research result might have implications for the future health of the research participant, especially if the researcher maintained contact with research participants over time and maintained a registry of research results:

“But something we try to keep in mind, and discuss sometimes with the researchers, is that it’s true that you’re just at the research stage and what you’re looking at right now isn’t necessarily meaningful, but...10 years down the road you may find that information is meaningful” [P27]

Respondents also described concerns about returning individual results both related and unrelated (unexpected or incidental) to the study aims. Overall, most respondents were supportive of returning validated individual results if the research subject desired; however, the provision of such results to individual research subjects was conditioned on a variety of factors.

Conditions for return of individual results

Foremost in the dialogue on conditions for ROR was the need to respect and consider the research subject’s desire to know or not know the research result. Some respondents also described the need to address the implications of returning the result, especially for the individual and/or their family (e.g., how to make sense of the result, especially if there was no medical intervention) and, to a lesser degree, for the researcher or research community (e.g., the infrastructure, resources and logistics that would be required to return research results to individual research subjects). Conditions for return are part of a dynamic circle of often interrelated and overlapping perspectives and criteria.

The most frequent conditions or criteria for returning an individual genetic research result favored a clinical utility perspective (25/31), where results should have “clinical significance”, “be serious or life threatening” and/or be medically actionable (e.g, a medical intervention was available). Respondents also supported return if withholding a research result would cause clinical or health harm, now or in the future. A personal utility perspective, based on respect for the research subject, was also expressed. Different justifications for this perspective included the position that returning information learned about a research subject was a form of reciprocity for participating in the research, that results could have personal meaning or empowerment for the research subject and could provide the opportunity to benefit from non-medical interventions (e.g., lifestyle changes, reproductive decision-making, investing in long term care or additional health or life insurance, changing career path). Some conditions, such as the need to validate a result in a “CLIA-approved laboratory” prior to return, reflected concerns from both clinical and personal utility perspectives.

Process to manage return of results

Role of IRB in deciding whether to return a particular research result—Most respondents indicated that a team of people should be involved in ROR decisions, including the research investigator, scientific and other medical peers, other experts in the field, a genetic counselor, a medical geneticist, and the individual’s treating physician. There was limited mention of the research subject or research advocate being involved in the decision making process, except to decide whether or not s/he wanted to know the result.

However, respondents did not agree on the specific role that the IRB should play in decision-making. Although many indicated that the IRB should be actively involved in

making the decision, others were not comfortable with this role and suggested that the IRB should “oversee the process” of decision-making, “I’m not sure that we have the expertise as a body to do that [make the decision]. We can raise questions and we can bring up issues that we think need to be addressed.” [P3] In this oversight role, the IRB would not be involved in actual decision-making per se, but would ensure that an appropriate, ethical process was followed for decision-making, including how the research result was communicated to the research participant. Experience with conducting or reviewing genetic research or years on the IRB did not seem to influence our respondent’s position on the role the IRB should play in this process.

Approaches to managing return of results—Several respondents described guidelines or approaches that were in place at their institution for returning results. However, none indicated that a formal process was established to determine whether or not to return an individual result, who should be involved in making that determination, and how the result should be communicated to the research subject, if return was warranted. Table 2 summarizes the approaches reported by our respondents to manage ROR. Some respondents indicated that the ROR issue is addressed at the beginning of the study, at the time of IRB review, especially for results related to the study aims. Researchers were expected to indicate in the IRB application and consent document whether research results will be returned and, if so, to offer the research subjects options for whether they wanted to know this information. This approach is similar to recommendations from the 1999 National Bioethics Advisory Commission.³³ One respondent indicated that the researcher should provide in the IRB application, “an honest and thought- through risk and benefit analysis [of whether or not meaningful results might be obtained and/or should be returned].” [P4] When ROR issues arose after initial IRB review, during the study or after study termination, many respondents considered their deliberations to be “more problematic”, mainly because there were no rules to follow. Many situations described at these times were consistent with finding an incidental result, “stumbling over a medical condition”, rather than one related to the research aims, “Especially if it’s [an incidental result] an issue that could significantly affect the life of the subject, I think it should be disclosed.” [P30]. Respondents indicated that situations arising *after* initial IRB review would be handled, “similar to other IRB issues” on a case-by-case basis, bringing in the appropriate experts. Many respondents voiced that an important factor in the decision making process is “whether there’s something you can do about it. ...if there’s not a step that the study participant could take to ward off bad consequences or you know to improve his or her health, then I don’t think so.” [P12]

As indicated above, some respondents described institution policies regarding CLIA-approved laboratory validation, “Our institution has taken a hard line, “No, you can’t [return results] if it’s not a CLIA-approved lab” [P27]), and/or that results be communicated by a professional trained in discussing genetic or genomic results with individuals. However, as described earlier, sometimes these policies, (e.g., no CLIA approved laboratory could perform an assay), were over-ruled to allow return.

Desire for Guidance

Although respondents were in favor of having some form of guidance regarding whether to return a research result, they differed in the type of information they felt was needed. Some wanted specific rules or regulations to follow, especially “because it still fees to me that it’s a new area.” [P11]. Others preferred “general ground rules” to follow to preserve the subjective and interpretive nature of IRB review, “I get really nervous about setting definitive [rules]. So I know everyone likes to operationalize everything, but I think that you could potentially miss a lot” and because of the different contexts of ROR situations,

“everything’s different, everything’s unique and everything can go one of ten different ways.”[P1].

Some respondents suggested plans for managing ROR situations (summarized in Table 3). This included an “optimal” approach to validating a research result and a two tiered process for decision-making. For assay validation it was suggested that the assay be repeated with a new sample (or second aliquot of the current sample), and ideally with a second validated test, preferably performed in a clinical laboratory, but definitely in a CLIA-approved laboratory. The two tiered process for decision-making included a first tier that would focus on “judging the significance, validity and actionability of the finding” and involve the researcher, his/her peer group, relevant clinicians and other experts in the field and the IRB. The second tier would consider the “psychosocial implications” of returning the finding to the research subject and would include the IRB, genetic counselors, the treating physician (if the research subject was also a patient), psychologists and ethicists. If both tiers favored return, the final step would include developing an appropriate process to communicate the research finding, including asking research participants whether they wanted to know a research finding, how the finding should be presented (e.g., in person or by phone) and by whom (e.g., caring, skilled professional); how to determine the appropriate content and scope of information to be communicated (e.g., probability, positive predictive value); and the type of follow-up counseling (e.g., genetic and/or psychological) and care needed, if any. This approach is similar to that described by Kohane et al.²⁰ Some respondents also recognized the requirement for an infrastructure and resources to support this process.

DISCUSSION

Although our data reflect the perspectives of our respondents and may not be generalizable to all IRB professionals, they offer important insights regarding the challenges that IRBs may face as they address return of results. First is the knowledge and expertise required to appropriately analyze these issues, especially in the context of a rapidly changing field where unprecedented amounts of genomic and phenotypic data are gained and shared at an extraordinary pace and the associations between these findings and disease development may change just as quickly. Second, although return of individual research results is not a new concept in clinical research—imaging studies have had a long history of revealing incidental findings that are communicated to research subjects^{34, 35}—return of results that have clinical relevance from *basic science* studies, especially in genomic research, is a new concern. For some of our respondents, the interview process itself provided one of the first opportunities for in-depth analysis of this issue. Third, the increase in genomic studies that IRBs anticipate reviewing in the future creates even more tension regarding how to address the issue of returning research results. Finally and perhaps most important, is the lack of national guidance on this issue upon which IRB professionals can anchor their decisions. Neither the Common Rule nor current OHRP guidance address the issue of return of individual research results.^{1, 32} Many respondents in our study were not comfortable developing local policies in isolation. Even those IRBs who have some guidelines in place, including the requirement to validate research results in a CLIA approved lab before return, found that some real life situations precluded them from complying with their own rule.

However, despite these challenges and expressions of perplexity, respondents in our study were very thoughtful in trying to integrate all legitimate perspectives on this issue, and articulated many of the concerns previously described in the literature.^{1, 5, 9-20, 31} These concerns reflected several dimensions of and individual thresholds for uncertainty, including the broad scope of the science juxtaposed with the highly contextual nature of each ROR scenario, and the challenges of appropriately assessing the analytical and clinical validity and clinical utility of a particular research result. The concern of having an individual act on

research results that may be incorrect or have low predictive power, or providing a research result that predicts a condition that has no medical intervention, fueled many of the uncertainties regarding how to appropriately assess potential risk and anticipated benefit. However, our respondents were firm in their position that a research participant's right to know/ not know information about themselves be respected and they supported the return of validated, medically actionable results. These positions are similar to those reported by genetic researchers.^{22, 36} Two studies with genetic/genomic researchers, using survey and qualitative methods, respectively, both identified clinical utility, respect for participants, and minimizing harm to participants as the common reasons for determining whether to return results.^{36, 22} Participants in the qualitative study also considered the IRB to be a main authority to see out to ensure that rules were being adhered to before researchers took action.²² However, as our study demonstrates, this can be a challenge when IRBs are still in the process of developing their own guidelines.

Only a few other studies have reported perspectives of IRBs on ROR.^{23,37} Lemke et al conducted a survey study with members of a professional group overseeing human subjects research where 78% agreed that an "ethical duty existed to return individual research results that could affect a participant's health or health care."²³ This view was also supported by the respondents in our study, along with contextual variables, such as the type of disease in question and the strength of the association of the result with disease development or response to therapy. The contextual nature of the ROR scenario was further highlighted by Wolf et al. in a study where IRB chairs were presented with a scenario in which banked DNA was used in a research study to evaluate risk of Alzheimer's disease.³⁷ Nearly all IRB chairs in Wolf's study expressed a desire to have predefined criteria regarding returning results.³⁷ Although respondents in our study also wanted guidance on ROR, the type of guidance differed among the individuals, some wanted more concrete guidelines, others preferred ground rules or best practices to guide them.

We found that respondents often used similar terms in different ways or the same term to encompass a general concept without defining or clarifying what that term meant. The lack of a common nomenclature is a long standing problem in human subjects research, especially in human specimen research and biobanking.³⁸ In our study, the frequent use of the terms *validated* or *clinical significance* without identifying the threshold for meeting those descriptions can hinder communication and decision-making between IRBs, researchers and research participants. Even in the research community, agreement is lacking regarding what these terms mean and how to measure them consistently.¹

We also learned new perspectives. First, many of our respondents expressed a need to consider the meaning of a research result not only today, but also in the future. This concern was described especially when the researcher is maintaining contact with the research subject over time and is maintaining a registry or database of research results. The implication was that researchers may have a long-term responsibility to their research subjects to monitor the literature for the clinical relevance, validity and utility of stored research results and communicate relevant information to the research subjects in the future. In contrast to the NHLBI recommendations suggesting that researchers are only responsible for ROR for the length of time of the study,¹⁸ our respondents did not put a time limit on the responsibility for monitoring currently uncertain results for future relevance. Second, we learned that IRB professionals have a range of views regarding whether the IRBs should play an active role in decision-making about returning individual results. Some respondents felt that the IRB should oversee the decision-making process, but not necessarily be a decision-maker. Finally, although there was agreement that results should be returned to individuals who want them, there was little mention about how to incorporate research

participant's views or definitions on what conditions would constitute personal or clinical utility.

The most challenging tension for IRBs in regulating the return of individual research results, however, may be how the practice blurs the line between research and clinical care.^{35, 39} IRBs are responsible for the ethical conduct of research, not the ethical conduct of clinical care. Research is meant to benefit society, not the individual research subject. Yet, in our study, and in society today, "a special power was associated with genomic information."⁴⁰ Our respondents expected that genomic or genetic studies would provide important clinical information for the research participant. And therein lies the conflict. The expectation for individual benefit is antithetical to the traditional concept of research. Addressing the return of individual research results that may be acted upon by the research participant crosses the boundary between research and clinical care. However, in our study and others, the communication of information that may benefit the research subject may also be considered part of the IRBs moral obligation in their role to protect research subjects.²³ It is not surprising that respondents expressed different views regarding the responsibility of the IRB to be actively involved in deciding whether a research result should be returned to an individual research subject. It is also not surprising that we lack national guidance.

Next steps: An IRB-researcher partnership

As IRBs are faced with real-life ROR situations, they will be forced to make decisions and develop management plans. Ground rules (and the range of acceptable interpretations) will need to be developed to address what conditions are either necessary or sufficient criteria for return (e.g., should actionable but unvalidated results be returned and what constitutes validity) and what situation trumps another. Although much effort is being devoted to the development of national and international policies for disclosing the results of genomic studies to research participants, there are opportunities at the local level to facilitate this process. One is the development of a partnership between IRB professionals and genomic researchers to approach the issue of return of results at their institution. Both IRB professionals and genomic researchers could benefit from a collaborative approach to addressing this issue, with each providing the necessary context and details to inform local management plans. Most importantly, research participants and the local community could also benefit from this partnership. The partnership could help assess local needs and develop management plans to meet those needs (Table 4). Training exercises involving contextually-based case scenarios could be developed to provide IRBs and researchers with practice in collectively conducting risk/benefit analyses, and opportunities to understand each other's concerns in addressing this issue. Similarly, such exercises could provide opportunities to develop a common nomenclature of relevant terms and examine the logistics, infrastructure and resources needed to support ROR. The partnership could lead to the development of a management plan that incorporates ways to address mutual concerns. In addition, the naturally occurring experiments that IRBs conduct in their research oversight responsibilities could be studied and analyzed, evaluating factors influencing development of different ROR policies and procedures. Having IRB professionals and researchers working together to address return of results at the local level can also inform development of policy at the national level.

Acknowledgments

The authors wish to thank Dr. Debra Skinner for her helpful discussions and guidance related to the methods. Dr. Skinner is the Director of the Methods Core of the University of North Carolina's Center for Genomics and Society. This study was supported by funding from the NHGRI ELSI program, Centers of Excellence in Ethical, Legal and Social Implications of Genetic Research: University of Washington, Seattle (P50HG3374), Case Western Reserve University, Cleveland (P50H3390) and the University of North Carolina (P50 HG4488) and the UNC

Eshelman School of Pharmacy. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Human Genome Research Institute or the National Institutes of Health.

References

1. Dressler LG. Disclosure of research results from cancer genomic studies: state of the science. *Clin Cancer Res.* Jul 1; 2009 15(13):4270–4276. [PubMed: 19549775]
2. Green ED, Guyer MS. Charting a course for genomic medicine from base pairs to bedside. *Nature.* 2011; 470(7333):204–213. [PubMed: 21307933]
3. Couzin-Frankel J. Human genome 10th anniversary What would you do? *Science.* Feb 11; 2011 331(6018):662–665. [PubMed: 21310980]
4. Wolf SM, Lawrenz FP, Nelson CA, et al. Managing incidental findings in human subjects research: analysis and recommendations. *J Law Med Ethics.* Summer;2008 36(2):219–248. 211. [PubMed: 18547191]
5. Wolf SM, Paradise J, Caga-anan C. The law of incidental findings in human subjects research: establishing researchers' duties. *J Law Med Ethics.* Summer;2008 36(2):361–383. 214. [PubMed: 18547206]
6. Juengst ET. Human genome research and the public interest: progress notes from an American science policy experiment. *Am J Hum Genet.* Jan; 1994 54(1):121–128. [PubMed: 8279462]
7. Clayton EW. Incidental findings in genetics research using archived DNA. *J Law Med Ethics.* Summer;2008 36(2):286–291. 212. [PubMed: 18547196]
8. Cho MK. Understanding incidental findings in the context of genetics and genomics. *J Law Med Ethics.* Summer;2008 36(2):280–285. 212. [PubMed: 18547195]
9. Dressler LG, Juengst ET. Thresholds and boundaries in the disclosure of individual genetic research results. *Am J Bioeth.* Nov-Dec;2006 6(6):18–20. [PubMed: 17085396]
10. Ravitsky V, Wilfond BS. Disclosing individual genetic results to research participants. *Am J Bioeth.* Nov-Dec;2006 6(6):8–17. [PubMed: 17085395]
11. Ossorio PN. Letting the gene out of the bottle: a comment on returning individual research results to participants. *Am J Bioeth.* Nov-Dec;2006 6(6):24–25. [PubMed: 17085399]
12. Dressler, L. Biobanking and disclosure of research results: Addressing the tension between professional boundaries and moral intuition. In: Solbakk, JH.; Holm, S.; Hoffman, B., editors. *The Ethics of Research Biobanking.* New York, NY: Springer; 2009. p. 85-99.
13. Shalowitz DI, Miller FG. Disclosing individual results of clinical research: implications of respect for participants. *JAMA.* Aug 10; 2005 294(6):737–740. [PubMed: 16091577]
14. Shalowitz DI, Miller FG. Communicating the results of clinical research to participants: attitudes, practices, and future directions. *PLoS Med.* May 13.2008 5(5):e91. [PubMed: 18479180]
15. Clayton EW, Ross LF. Implications of disclosing individual results of clinical research. *JAMA.* Jan 4.2006 295(1):37. [PubMed: 16391213]
16. Bookman EB, Langehorne AA, Eckfeldt JH, et al. Reporting genetic results in research studies: summary and recommendations of an NHLBI working group. *Am J Med Genet A.* May 15; 2006 140(10):1033–1040. [PubMed: 16575896]
17. Fernandez CV, Weijer C. Obligations in offering to disclose genetic research results. *Am J Bioeth.* Nov-Dec;2006 6(6):44–46. [PubMed: 17085409]
18. Fabsitz RR, McGuire A, Sharp RR, et al. Ethical and practical guidelines for reporting genetic research results to study participants: updated guidelines from a National Heart, Lung, and Blood Institute working group. *Circ Cardiovasc Genet.* Dec 1; 2010 3(6):574–580. [PubMed: 21156933]
19. Knoppers BM, Joly Y, Simard J, Durocher F. The emergence of an ethical duty to disclose genetic research results: international perspectives. *Eur J Hum Genet.* Nov; 2006 14(11):1170–1178. [PubMed: 16868560]
20. Kohane IS, Mandl KD, Taylor PL, Holm IA, Nigrin DJ, Kunkel LM. Medicine. Reestablishing the researcher-patient compact. *Science.* May 11; 2007 316(5826):836–837. [PubMed: 17495156]
21. NIH. [June 15, 2011] Points to Consider for IRBs and Institutions in their Review of Data Submission Plans for Institutional Certifications Under NIH's Policy for Sharing of Data Obtained

- in NIH Supported or Conducted Genome-Wide Association Studies (GWAS). 2007. Available at: http://grants.nih.gov/grants/gwas/gwas_ptc.pdf
22. Meacham MC, Starks H, Burke W, Edwards K. Researcher perspectives on disclosure of incidental findings in genetic research. *J Empir Res Hum Res Ethics*. Sep; 2010 5(3):31–41. [PubMed: 20831419]
 23. Lemke AA, Trinidad SB, Edwards KL, Starks H, Wiesner GL. GRRIP Consortium. Attitudes toward genetic research review: results from a national survey of professionals involved in human subjects protection. *J Empir Res Hum Res Ethics*. Mar; 2010 5(1):83–92. [PubMed: 20235866]
 24. Edwards KL, Lemke AA, Trinidad SB, et al. Attitudes toward Genetic Research Review: Results from a Survey of Human Genetics Researchers. *Public Health Genomics*. Apr 11. 2011 epub ahead of print.
 25. Patton, M., editor. *Qualitative evaluation and research methods*. 3. Thousand Oaks: Sage; 2002.
 26. Guba EG. Criteria for assessing the trustworthiness of naturalistic inquiries. *Educational Communication and Technology*. 1981; 29(2):75–91.
 27. Lincoln, Y.; Guba, A. *Naturalistic inquiry*. Beverly Hills: Sage; 1985.
 28. Charmaz, K. *Constructing Grounded Theory - A Practical Guide Through Qualitative Analysis*. 1. London: SAGE Publications Ltd; 2006. Coding in Grounded Theory Paractice; p. 42-71.
 29. Strauss, A.; Corbin, J. *Basics of qualitative research: Grounded theory procedures and techniques*. Newbury Park, CA: Sage; 1990.
 30. Denzin, NK. *The research act: A theoretical introduction to sociological methods*. Engelwood Cliffs: Prentice Hall; 1989.
 31. Dressler, L. Disclosure of genetic research results: professional boundaries and moral intuition. In: Helge, J., editor. *Mapping the Language of Research Biobanks and Health Registries: From traditional to research biobanks*. Springer Verlag; 2009. in press
 32. OPRR. [June 15, 2011] Human Genetic Research. OPRR Protecting Human Research Subjects Institutional Review Board Guidebook. 1993. <http://www.genome.gov/10001752>
 33. NBAC. *Research Involving Human Biological Materials: Ethical Issues and Policy Guidance*. 1 Report and Recommendations of the National Bioethics Advisory Commission. 1999; <http://bioethics.georgetown.edu/nbac/hbm.pdf>.
 34. Kohane IS, Masys DR, Altman RB. The incidentalome: a threat to genomic medicine. *JAMA*. Jul 12; 2006 296(2):212–215. [PubMed: 16835427]
 35. Wolf SM, Kahn JP, Lawrenz FP, Nelson CA. The incidentalome. *JAMA*. Dec 20; 2006 296(23): 2800–2801. [PubMed: 17179453]
 36. Heaney C, Tindall G, Lucas J, Haga SB. Researcher practices on returning genetic research results. *Genet Test Mol Biomarkers*. Dec; 2010 14(6):821–827. [PubMed: 20939736]
 37. Wolf LE, Catania JA, Dolcini MM, Pollack LM, Lo B. IRB Chairs' Perspectives on Genomics Research Involving Stored Biological Materials: Ethical Concerns and Proposed Solutions. *J Empir Res Hum Res Ethics*. Dec; 2008 3(4):99–111. [PubMed: 19385758]
 38. Dressler, L. National Cancer Policy Board, Institutes of Medicine and Research Council of the National Academies. *Human Specimens, Cancer Research and Drug Development: How Science Policy can Promote Progress and Protect Research Participants*. 2005. <http://www.iom.edu/CMS/3798/12774/26207.aspx>
 39. Miller FG, Rosenstein DL, DeRenzo EG. Professional integrity in clinical research. *JAMA*. Oct 28; 1998 280(16):1449–1454. [PubMed: 9801009]
 40. Burke W, Diekema DS. Ethical issues arising from the participation of children in genetic research. *J Pediatr*. Jul; 2006 149(1 Suppl):S34–38. [PubMed: 16829241]

Table 1

IRB perspectives on returning individual results to research participants

Concerns/Positions	Quotation from transcripts
Complexity of inter-related context dependent issues	[P3] "Oh that is a loaded [question] ...But my guess is that it depends totally on the situation, it depends on what disease you're talking about, it depends on what are the ramifications of that disease, you know how strong the data are. I mean how valid is it? I mean is it something that they've seen one time? So I think all those things have to be taken into consideration and then an informed judgment made as to what's appropriate to share back with the subject and what's not. What are the things that have been established without a doubt clinically?... Then absolutely that stuff should be communicated back to the subject. But we're just now sort of getting into those areas and I don't want to say a fishing expedition, but you know it's still more exploratory, and trying to figure out what the relevance of things are, then I think you can do a disservice by frightening a subject by telling, giving them too much information, information that you have absolutely no idea of whether it's, relevant [to their health] ..."
Difficulty in evaluating implications for research subjects	[P4] "...it [genetic research] is the piece I have the greatest ignorance about. You know a lot of the other stuff in IRB you can look up in a manual or in regulations or you've been taught about it, you understand [it]. Genetics is something new. I don't understand genetics, but I understand a bit why it's very important to human subjects,...I feel uncomfortable being able to recognize if a subject's genetic rights are being considered."
IRB's moral responsibility	[P21] "And then the question has come up, what do you [the IRB] do if you uncover one of these [genes] in somebody, do you have a duty to disclose?"
Right to know/right not to know	[P19]"I think if the research subject wants to know, yes. So I think they should be asked, 'Do you want to know the result of this study?' and if the answer is 'Yes, I want to know,' I think the answer is yes."
Validity of result (analytic and clinical)	[P15] "So I think we do have to have some idea of how robust [are] the assays or the method, how well it's performed in that particular laboratory, what their track record is. Maybe it should be repeated someplace else or under a different circumstance, a different lab or using a different method before you give out that answer." [P23] "It depends... if there is a well-established connection with the disease [of interest], the researcher has a responsibility to provide that information. But if there is not any clarity between the relationship of the test, the presence or absence of genetic markers and any disease, then that information shouldn't be given to the patient because it just confuses and confounds things."
Absolute right to know	[P16] "I think as a general ethical and moral principle, researchers should disclose information, and I think it raises a serious question in my mind about the ethical nature of a study that informs patients that 'We will not disclose information to you, even if it's significant.'"
Return mutation status not interpretation	[P2] "So I don't have a problem with the researchers telling the person, "You have this gene". I have a problem with researchers making conclusions based on that research [and communicating that to the research subject since] ...it is still research."

Table 2Approaches for managing return of results^a

A. At the time study is submitted to the Institutional Review Board (IRB) for review (researcher responsibility)

- Indicate intent to return or not in the informed consent and IRB application
- Ensure transparency in consent process so research subject understands what will and will not be returned
- Justify the rationale for returning or not returning results in consent process and IRB application
- If return is intended, give the research subject option to receive or not receive results as part of informed consent process and document
- Consider the future meaning of a currently uncertain clinical finding

A. During the course of the study or after study completion (IRB/researcher responsibility)

- High quality of assay methodology and result interpretation
 - Only results that have been validated in a Clinical Laboratory Improvement Act (CLIA) approved laboratory should be returned to a research subject
 - Only medical professionals (e.g., genetic counselors, medical geneticists) with appropriate expertise should return results
-

^aThis table represents approaches or guidelines described by our respondents that are in place at their institutional IRB

Table 3**Suggestions for Returning a Research Result^a****I. Two tiered process for decision-making:**

Tier 1: Assess clinical significance: Convene an expert group consisting of investigators, clinicians, medical geneticists, treating physicians, Institutional Review Board (IRB), and others to evaluate the clinical relevance and validity of the finding (where analytic validity would involve a second sample evaluated in a Clinical Laboratory Improvement Act (CLIA) laboratory by same or different method) and whether the result is medically actionable.

Tier 2: Assess psychosocial and moral implications: Convene an expert group consisting of genetic counselors, medical geneticist, treating physician, psychologist/psychiatrist, IRB, and others to: 1. evaluate the psychological, social, emotional implications of returning the result to the research subject and/or their family; 2. consider the personal meaning/utility of the result for the research subject and/or their family; 3. consider the moral obligation of the IRB/researcher to return the result

If the evaluation of the two tiers support return, develop a process for communicating the result to the research subject and/or family.

II. Communicating the research result:

- Determine if the research subject wants to know the result
- Research result communicated by a medical professional with expertise (e.g., genetic counselor, medical geneticist).
- Consider provision for follow up care/counseling
- Consider the resources, infrastructure and logistics needed to support the process

^aThis table summarizes and synthesizes suggestions made by respondents to optimally manage return of individual results.

Table 4**IRB -Researcher Partnership to Address Return of Individual Genomic Results (ROR)**

Opportunities and Issues to Consider for IRBs and genomic researchers:

- Provide collaborative education for IRB members and genomic researchers, including principles of genomics research and ethical/social/process implications of return
 - Develop a common nomenclature of relevant terms
 - Conduct ROR training using a spectrum of case-based scenarios
 - Consider implications for local research participants, including implications for native or minority populations
 - Conduct training in ROR risk/benefit analysis, including clinical and psychosocial assessment
 - Consider logistics, infrastructure and resources needed for return of individual results
 - Develop a management plan
 - Implement and evaluate management plan
 - Consider cross-site IRB-researcher partnerships and management plans
-